MyMD Pharmaceuticals, Inc. (0A8D.L)

3.2300 +0.3100 (+10.62%) At close: 05:13PM BST

MyMD Pharmaceuticals, Inc.

855 North Wolfe Street
Suite 601
Baltimore, MD 21205
United States
856 848 8698
https://www.mymd.com

Sector(s): 
Industry: 
Full-time employees: 6

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Christopher C. Chapman Jr., M.D.	President, Chief Medical Officer & Director	665.76k	N/A	1953
Mr. Ian Rhodes CPA	Interim Chief Financial Officer	162k	N/A	1973
Dr. Jenna Brager M.S., Ph.D., R.N.	Executive Vice President of Drug Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

Corporate governance

MyMD Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.